PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.
Clin Cancer ResSep 1, 2026
Jing Guo, Yuliang Wu, Wei Huang et al.
✦ AI-curated · Sources linked
In 30 seconds
This first-in-human phase I trial evaluated the safety and efficacy of GC203, a genetically modified tumor-infiltrating lymphocyte (TIL) product, in 18 heavily pretreated patients with recurrent ovarian cancer. The study found an unconfirmed objective response rate of 33.3% and a median overall survival of 17.1 months, indicating promising efficacy in this challenging population.
Key findings
- The unconfirmed objective response rate was 33.3% (6/18 patients).
- The disease control rate reached 83.3%.
- Median progression-free survival was 7.2 months (95% CI, 1-13.4).
- Median overall survival was 17.1 months (95% CI, 9.5-24.7).
Why it matters
Recurrent ovarian cancer presents significant treatment challenges, and the promising results from the GC203 regimen may offer new therapeutic options for heavily pretreated patients, addressing a critical unmet need in oncology.